SWISS drugs group Roche reported a 3% increase in first-quarter sales to Swfr6.73bn (£3.12bn), below market expectations. It said underlying sales growth was much stronger but the figures were held back by the strength of the Swiss franc against the dollar.
Create a FREE account to continue reading
Registration is a free and easy way to support our journalism.
Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.
Thank you for registering
Please refresh the page or navigate to another page on the site to be automatically logged in